Pharmaceuticals

ALTAMIRA THERAPEUTICS LTD

Altamira Therapeutics Reports Reduced Net Loss in 2025 Fiscal Year

ALTAMIRA THERAPEUTICS LTD to Release FY2025 Annual Earnings on March 31, 2026 Pre-Market EST

Altamira Medica Receives NMPA Market Approval for Bentrio Nasal Spray

Altamira Medica Obtains EU MDR Certification for Bentrio Nasal Spray

Altamira Therapeutics Ltd released FY2025 Q1 earnings on August 29 (EST), actual revenue USD 0, actual EPS USD -0.1529

Altamira Therapeutics Ltd released FY2025 Semi-Annual Earnings on August 29 Pre-Market (EST), Actual Revenue: USD 0 (Forecast: USD 0), Actual EPS: USD -0.3059 (Forecast: USD --)

Altamira Therapeutics Ltd released FY2025 Q2 earnings on August 29 Pre-Market EST, actual revenue USD 0, actual EPS USD -0.1529

Altamira Therapeutics Ltd. plans to reduce operating expenses by partially divesting its ATAG subsidiary

Altamira Therapeutics Reports 2025 First Half Year Financials and Advances RNA Delivery Technology

ALTAMIRA THERAPEUTICS LTD to Release FY2025 Semi-Annual Earnings on August 29, 2025 (EST), Forecast Revenue USD 0, EPS --

Altamira Therapeutics Ltd released FY2024 Q3 earnings on April 30, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.5713

Altamira Therapeutics Ltd released FY2024 9 Months Earnings on April 30 (EST), Actual Revenue: USD 0, Actual EPS: USD -2.6773

Altamira Therapeutics Ltd released FY2024 earnings on April 30 Pre-Market EST, actual revenue USD 0, actual EPS USD -2.9861

Altamira Therapeutics Ltd released FY2024 Q4 earnings on April 30 Pre-Market EST, actual revenue USD 0, actual EPS USD -0.5713

Altamira Therapeutics Ltd to Release FY2024 Earnings Report on April 30, 2025 Pre-Market EST

Altamira Therapeutics Ltd released FY2024 Q1 earnings on September 24, 2024 (EST) with actual revenue of 0 USD and EPS of -1.0529 USD

Altamira Therapeutics Ltd released FY2023 Q1 earnings on September 24, 2024 (EST) with actual revenue of 0 USD and EPS of -14.1571 USD

Altamira Therapeutics Ltd released FY2023 Q2 earnings on September 24 Pre-Market (EST), with actual revenue of 0 USD and EPS of -14.1571 USD

Altamira Therapeutics Ltd released FY2024 Semi-Annual Earnings on September 24 Pre-Market (EST), with actual revenue of 0 USD and EPS of -2.1059 USD

Altamira Therapeutics Ltd released FY2024 Q2 earnings on September 24 Pre-Market (EST), with actual revenue of 0 USD and EPS of -1.0529 USD

OPTIMI HEALTH CORP

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Micware

GCL Global

Silexion Therapeutics

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Bristol-Myers Squibb Company

CYTOF

VXRT

SBIO

IBBQ

Vax has appointed James B. Breitmeyer, M.D., Ph.D. to its Board of Directors, effective immediately. He is the current CEO of Altay Therapeutics and has extensive experience in the biotech sector. The Board has determined that he meets independence standards and will receive standard compensation and indemnification. This appointment follows a recommendation by the Nominating and Governance Committee.

TradingView

Vaxart

ALPS Medical Breakthrough

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

Ark Genomic Revolution ETF

iShares Global Healthcare

iShares US Pharma

SPDR S&P Biotech

VG Health

ESC NEUBASE THERAPEUTI

Alta Equipment

Nano Labs

Plus Therapeutics

Oncolytics Biotech

Bavarian Nordic A/S

Nordic

NORDICUS PARTNERS CORP

Bitwise Avalanche ETF

Eli Lilly

Cadence Design

Cadence Capital Limited

Vertex Pharma

Axogen

Frontier, Inc. (Yamaguchi)

Change, Inc. (Japan)

OnKure Therapeutics

Tenon Medical

ALTA EQUIPMENT GROUP INC 10% DEP SH 1/1000TH CUM PFD SER A USD25

TENON MEDICAL INC C/WTS 16/06/2028 (TO PUR COM)

Vax appoints James B. Breitmeyer to its Board

GRTX

NBSE.ESC

Kailera Therapeutics and Alamar Biosciences have filed for U.S. IPOs. Kailera, focused on weight loss drugs, plans to list on Nasdaq under "KLRA" with its lead candidate, ribupatide, in Phase 3 trials. The company reported a $149M net loss in 2025. Alamar, specializing in proteomics, aims to list under "ALMR" and reported $74.2M revenue in 2025, with a narrowed net loss of $29.8M. Both companies are seeking to raise capital through their IPOs.

businessinsider

Galera Therapeutics

Aligos Therapeutics

Karyopharm Therap

MBX Biosciences

Proshares Ultra Nasdaq Biotech

GLP-1 developer Kailera, proteomics firm Alamar file for U.S. IPOs

IPFXU

The week of March 23rd, 2026, saw significant filing activity in the aerospace and healthcare sectors, despite no traditional IPOs. Three blank check companies, including Inflection Point Acquisition VI, raised a total of $220 million targeting technology-enabled businesses. Other notable filings included Alamar Biosciences and Kailera Therapeutics, each raising $100 million in the healthcare sector. Additionally, several SPACs, such as Collective Acquisition II and Oceanhawk Acquisition, also entered the pipeline with substantial funding plans.

RenaissanceCapital

Inflection Point Acquisition VI - Unit

Inflection Point  Acquisition

Kalaris Therapeutics

Inflection Point Acquisition IV

Bleichroeder Acquisition I - Unit

US Weekly Recap: Aerospace and healthcare issuers drive late-March filing activity

GDTC

CytoMed Therapeutics Limited (NASDAQ: GDTC) has issued a statement refuting misleading claims about its research and clinical progress. The company emphasizes its focus on CAR γδ T cell therapies and iPSC-derived γδ NKT cell therapies, with its lead CAR γδ T cell program currently in a first-in-human clinical trial. CytoMed asserts that any claims regarding its regulatory status or financial transparency that contradict its statements are inaccurate. The company remains committed to responsible development and accurate communication with stakeholders.

StockTitan

Cytomed Therapeutics

CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress | GDTC Stock News

ALTAMIRA THERAPEUTICS LTD(CYTOF.US)

Vax appoints James B. Breitmeyer to its Board

GLP-1 developer Kailera, proteomics firm Alamar file for U.S. IPOs

US Weekly Recap: Aerospace and healthcare issuers drive late-March filing activity

CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress | GDTC Stock News